Lee Silverman Voice Treatment to Improve Speech in Parkinson’s Disease: A Systemic Review and Meta-Analysis
Parkinson's Disease · 27.12.2021 · 2021 · 1-10
DOI: 10.1155/2021/3366870 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Parkinson's Disease, erschienen am 27.12.2021. Verfasst von Tingting Pu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Dali University, Yunnan 671000, Dali, China. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chengdu Medical College, Chengdu Science and Technology Bureau Focused on Research and Development Support Plan, Popular Scientific Research Project of Sichuan Health Commission.
Abstract (Originalsprache)
Background
Speech changes occur in the early stages of Parkinson’s disease (PD) and cause communication difficulties, leading to social isolation. Lee Silverman voice treatment (LSVT) is a speech therapy approach designed to improve patients’ language and voice capabilities.
Objective
The effectiveness of the LSVT was compared with that of other speech interventions or no treatment to evaluate PD patients with dysarthria.
Design
Systematic review with meta-analysis of randomized trials. Data Sources: PubMed, Embase, Cochrane Library, CNKI, and SinoMed library were searched from inception to December 2021 related to PD and LSVT.
Method
Abstracts were screened and reviewed against the eligibility criteria (intervention group participants were PD assessed based on LSVT (LSVT Loud) and randomized control).
Result
Ten randomized controlled trials were identified on speech symptoms in patients with PD. Compared with the respiratory therapy (RET) exercise, or no training group, a significant improvement was detected in the sound press level (SPL) after immediate treatment during the reading of vowel and rainbow passages and an increase in semitone standard deviation (STSD). Furthermore, the LSVT training significantly increased the participants’ scores on unified Parkinson’s disease rating scale (UPDRS-III) and speech intelligibility.
Conclusion
This meta-analysis demonstrated the efficacy of LSVT in increasing vocal loudness and functional communication among individuals with PD. However, most studies included participants with mild-moderate PD. Thus, additional randomized controlled trials (RCTs) with large sample sizes are needed to validate the efficacy of LSVT in patients with different progressions of PD, including severe PD.
Autor:innen und Institutionen
- School of Pharmacy, Dali University, Yunnan 671000, Dali, China.
- Department of Public Health, Chengdu Medical College, Sichuan 610500, Chengdu, China.
- Department of Physiology, Chengdu Medical College, Sichuan 610500, Chengdu, China.
- Beijing Institute of Basic Medical Sciences, Beijing 100850, China.
ORCID-Profile: Xiechuan Weng, Fan Xu
Förderung
- Chengdu Medical College
- Chengdu Science and Technology Bureau Focused on Research and Development Support Plan
- Popular Scientific Research Project of Sichuan Health Commission
- Sichuan Undergraduate Innovation and Startup Program Funding Support
Zitieren
APA
Pu, T., Huang, M., Kong, X., Wang, M., Chen, X., Feng, X., Wei, C., Weng, X., & Xu, F. (2021). Lee Silverman Voice Treatment to Improve Speech in Parkinson’s Disease: A Systemic Review and Meta-Analysis. Parkinson's Disease, 2021, 1-10. https://doi.org/10.1155/2021/3366870
Vancouver
Pu T, Huang M, Kong X, Wang M, Chen X, Feng X, et al. Lee Silverman Voice Treatment to Improve Speech in Parkinson’s Disease: A Systemic Review and Meta-Analysis. Parkinson's Disease. 2021;2021:1-10. doi:10.1155/2021/3366870
BibTeX
@article{Pu2021,
author = {Pu, Tingting and Huang, Min and Kong, Xiangyu and Wang, Meng and Chen, Xiangling and Feng, Xixi and Wei, Changyou and Weng, Xiechuan and Xu, Fan},
title = {Lee Silverman Voice Treatment to Improve Speech in Parkinson’s Disease: A Systemic Review and Meta-Analysis},
journal = {Parkinson's Disease},
year = {2021},
volume = {2021},
pages = {1--10},
doi = {10.1155/2021/3366870}
}
EUVIMED